Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

Joleen M Hubbard, Charles Erlichman, David O. Toft, Rui Qin, Bridget A. Stensgard, Sara Felten, Cynthia Ten Eyck, Gretchen Batzel, S. Percy Ivy, Paul Haluska

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: To determine the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLT) of 17-AAG, gemcitabine and/or cisplatin. Levels of the proteins Hsp90, Hsp70 and ILK were measured in peripheral blood mononuclear cell (PMBC) lysates to assess the effects of 17-AAG. Experimental design: Phase I dose-escalating trial using a "3+3" design performed in patients with advanced solid tumors. Once the MTD of gemcitabine + 17-AAG + cisplatin was determined, dose escalation of 17-AAG with constant doses of gemcitabine and cisplatin was attempted. After significant hematologic toxicity occurred, the protocol was amended to evaluate three cohorts: gemcitabine and 17-AAG; 17-AAG and cisplatin; and gemcitabine, 17-AAG and cisplatin with modified dosing. Results: The 39 patients enrolled were evaluable for toxicity and response. The MTD for cohort A was 154 mg/m 2 of 17-AAG, 750 mg/m 2 of gemcitabine, and 40 mg/m 2 of cisplatin. In cohort A, DLTs were observed at the higher dose level and included neutropenia, hyperbilirubinemia, dehydration, GGT elevation, hyponatremia, nausea, vomiting, and thrombocytopenia. The MTD for cohort C was 154 mg/m 2 of 17-AAG and 750 mg/m 2 of gemcitabine, with one DLT observed (alkaline phosphatase elevation) observed. In cohort C, DLTs of thrombocytopenia, fever and dyspnea were seen at the higher dose level. The remaining cohorts were closed to accrual due to toxicity. Six patients experienced partial responses. Mean Hsp90 levels were decreased and levels of Hsp70 were increased compared to baseline. Conclusions: 17-AAG in combination with gemcitabine and cisplatin demonstrated antitumor activity, but significant hematologic toxicities were encountered. 17-AAG combined with gemcitabine is tolerable and has demonstrated evidence of activity at the MTD. The recommended phase II dose is defined as 154 mg/m 2 of 17-AAG and 750 mg/m 2 of gemcitabine, and is currently being investigated in phase II studies in ovarian and pancreatic cancers. There is no recommended phase II dose for the cisplatin-containing combinations.

Original languageEnglish (US)
Pages (from-to)473-480
Number of pages8
JournalInvestigational New Drugs
Volume29
Issue number3
DOIs
StatePublished - Jun 2011

Fingerprint

tanespimycin
gemcitabine
Cisplatin
Maximum Tolerated Dose
Neoplasms
Thrombocytopenia

Keywords

  • 17-allyaminogeldanamycin
  • Cisplatin
  • Gemcitabine
  • Heat shock protein 70
  • Heat shock protein 90
  • ILK
  • Phase I

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. / Hubbard, Joleen M; Erlichman, Charles; Toft, David O.; Qin, Rui; Stensgard, Bridget A.; Felten, Sara; Ten Eyck, Cynthia; Batzel, Gretchen; Ivy, S. Percy; Haluska, Paul.

In: Investigational New Drugs, Vol. 29, No. 3, 06.2011, p. 473-480.

Research output: Contribution to journalArticle

Hubbard, JM, Erlichman, C, Toft, DO, Qin, R, Stensgard, BA, Felten, S, Ten Eyck, C, Batzel, G, Ivy, SP & Haluska, P 2011, 'Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors', Investigational New Drugs, vol. 29, no. 3, pp. 473-480. https://doi.org/10.1007/s10637-009-9381-y
Hubbard, Joleen M ; Erlichman, Charles ; Toft, David O. ; Qin, Rui ; Stensgard, Bridget A. ; Felten, Sara ; Ten Eyck, Cynthia ; Batzel, Gretchen ; Ivy, S. Percy ; Haluska, Paul. / Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. In: Investigational New Drugs. 2011 ; Vol. 29, No. 3. pp. 473-480.
@article{216363bffce44cfa876c5c06d07154db,
title = "Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors",
abstract = "Purpose: To determine the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLT) of 17-AAG, gemcitabine and/or cisplatin. Levels of the proteins Hsp90, Hsp70 and ILK were measured in peripheral blood mononuclear cell (PMBC) lysates to assess the effects of 17-AAG. Experimental design: Phase I dose-escalating trial using a {"}3+3{"} design performed in patients with advanced solid tumors. Once the MTD of gemcitabine + 17-AAG + cisplatin was determined, dose escalation of 17-AAG with constant doses of gemcitabine and cisplatin was attempted. After significant hematologic toxicity occurred, the protocol was amended to evaluate three cohorts: gemcitabine and 17-AAG; 17-AAG and cisplatin; and gemcitabine, 17-AAG and cisplatin with modified dosing. Results: The 39 patients enrolled were evaluable for toxicity and response. The MTD for cohort A was 154 mg/m 2 of 17-AAG, 750 mg/m 2 of gemcitabine, and 40 mg/m 2 of cisplatin. In cohort A, DLTs were observed at the higher dose level and included neutropenia, hyperbilirubinemia, dehydration, GGT elevation, hyponatremia, nausea, vomiting, and thrombocytopenia. The MTD for cohort C was 154 mg/m 2 of 17-AAG and 750 mg/m 2 of gemcitabine, with one DLT observed (alkaline phosphatase elevation) observed. In cohort C, DLTs of thrombocytopenia, fever and dyspnea were seen at the higher dose level. The remaining cohorts were closed to accrual due to toxicity. Six patients experienced partial responses. Mean Hsp90 levels were decreased and levels of Hsp70 were increased compared to baseline. Conclusions: 17-AAG in combination with gemcitabine and cisplatin demonstrated antitumor activity, but significant hematologic toxicities were encountered. 17-AAG combined with gemcitabine is tolerable and has demonstrated evidence of activity at the MTD. The recommended phase II dose is defined as 154 mg/m 2 of 17-AAG and 750 mg/m 2 of gemcitabine, and is currently being investigated in phase II studies in ovarian and pancreatic cancers. There is no recommended phase II dose for the cisplatin-containing combinations.",
keywords = "17-allyaminogeldanamycin, Cisplatin, Gemcitabine, Heat shock protein 70, Heat shock protein 90, ILK, Phase I",
author = "Hubbard, {Joleen M} and Charles Erlichman and Toft, {David O.} and Rui Qin and Stensgard, {Bridget A.} and Sara Felten and {Ten Eyck}, Cynthia and Gretchen Batzel and Ivy, {S. Percy} and Paul Haluska",
year = "2011",
month = "6",
doi = "10.1007/s10637-009-9381-y",
language = "English (US)",
volume = "29",
pages = "473--480",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

AU - Hubbard, Joleen M

AU - Erlichman, Charles

AU - Toft, David O.

AU - Qin, Rui

AU - Stensgard, Bridget A.

AU - Felten, Sara

AU - Ten Eyck, Cynthia

AU - Batzel, Gretchen

AU - Ivy, S. Percy

AU - Haluska, Paul

PY - 2011/6

Y1 - 2011/6

N2 - Purpose: To determine the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLT) of 17-AAG, gemcitabine and/or cisplatin. Levels of the proteins Hsp90, Hsp70 and ILK were measured in peripheral blood mononuclear cell (PMBC) lysates to assess the effects of 17-AAG. Experimental design: Phase I dose-escalating trial using a "3+3" design performed in patients with advanced solid tumors. Once the MTD of gemcitabine + 17-AAG + cisplatin was determined, dose escalation of 17-AAG with constant doses of gemcitabine and cisplatin was attempted. After significant hematologic toxicity occurred, the protocol was amended to evaluate three cohorts: gemcitabine and 17-AAG; 17-AAG and cisplatin; and gemcitabine, 17-AAG and cisplatin with modified dosing. Results: The 39 patients enrolled were evaluable for toxicity and response. The MTD for cohort A was 154 mg/m 2 of 17-AAG, 750 mg/m 2 of gemcitabine, and 40 mg/m 2 of cisplatin. In cohort A, DLTs were observed at the higher dose level and included neutropenia, hyperbilirubinemia, dehydration, GGT elevation, hyponatremia, nausea, vomiting, and thrombocytopenia. The MTD for cohort C was 154 mg/m 2 of 17-AAG and 750 mg/m 2 of gemcitabine, with one DLT observed (alkaline phosphatase elevation) observed. In cohort C, DLTs of thrombocytopenia, fever and dyspnea were seen at the higher dose level. The remaining cohorts were closed to accrual due to toxicity. Six patients experienced partial responses. Mean Hsp90 levels were decreased and levels of Hsp70 were increased compared to baseline. Conclusions: 17-AAG in combination with gemcitabine and cisplatin demonstrated antitumor activity, but significant hematologic toxicities were encountered. 17-AAG combined with gemcitabine is tolerable and has demonstrated evidence of activity at the MTD. The recommended phase II dose is defined as 154 mg/m 2 of 17-AAG and 750 mg/m 2 of gemcitabine, and is currently being investigated in phase II studies in ovarian and pancreatic cancers. There is no recommended phase II dose for the cisplatin-containing combinations.

AB - Purpose: To determine the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLT) of 17-AAG, gemcitabine and/or cisplatin. Levels of the proteins Hsp90, Hsp70 and ILK were measured in peripheral blood mononuclear cell (PMBC) lysates to assess the effects of 17-AAG. Experimental design: Phase I dose-escalating trial using a "3+3" design performed in patients with advanced solid tumors. Once the MTD of gemcitabine + 17-AAG + cisplatin was determined, dose escalation of 17-AAG with constant doses of gemcitabine and cisplatin was attempted. After significant hematologic toxicity occurred, the protocol was amended to evaluate three cohorts: gemcitabine and 17-AAG; 17-AAG and cisplatin; and gemcitabine, 17-AAG and cisplatin with modified dosing. Results: The 39 patients enrolled were evaluable for toxicity and response. The MTD for cohort A was 154 mg/m 2 of 17-AAG, 750 mg/m 2 of gemcitabine, and 40 mg/m 2 of cisplatin. In cohort A, DLTs were observed at the higher dose level and included neutropenia, hyperbilirubinemia, dehydration, GGT elevation, hyponatremia, nausea, vomiting, and thrombocytopenia. The MTD for cohort C was 154 mg/m 2 of 17-AAG and 750 mg/m 2 of gemcitabine, with one DLT observed (alkaline phosphatase elevation) observed. In cohort C, DLTs of thrombocytopenia, fever and dyspnea were seen at the higher dose level. The remaining cohorts were closed to accrual due to toxicity. Six patients experienced partial responses. Mean Hsp90 levels were decreased and levels of Hsp70 were increased compared to baseline. Conclusions: 17-AAG in combination with gemcitabine and cisplatin demonstrated antitumor activity, but significant hematologic toxicities were encountered. 17-AAG combined with gemcitabine is tolerable and has demonstrated evidence of activity at the MTD. The recommended phase II dose is defined as 154 mg/m 2 of 17-AAG and 750 mg/m 2 of gemcitabine, and is currently being investigated in phase II studies in ovarian and pancreatic cancers. There is no recommended phase II dose for the cisplatin-containing combinations.

KW - 17-allyaminogeldanamycin

KW - Cisplatin

KW - Gemcitabine

KW - Heat shock protein 70

KW - Heat shock protein 90

KW - ILK

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=79955603500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955603500&partnerID=8YFLogxK

U2 - 10.1007/s10637-009-9381-y

DO - 10.1007/s10637-009-9381-y

M3 - Article

C2 - 20082116

AN - SCOPUS:79955603500

VL - 29

SP - 473

EP - 480

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -